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Executive Summary 
 
 
Substance identification 
N-Ethylnorpentylone (IUPAC name: 1-(2H-1,3-benzodioxol-5-yl)-2-(ethylamino)pentan-1-one) is a 
ring-substituted synthetic cathinone analog. It originally emerged in the 1960s during 
pharmaceutical drug development efforts. Another common name used widely is N-
ethylpentylone. On the streets, N-ethylnorpentylone is most likely available as the racemic mixture 
and it might be obtained from Internet retailers. In the United States of America (USA), this 
substance was detected for the first time in 2014 but began to emerge more prominently in 2016 
both in the USA and other UN Member States. Seizures indicate that N-ethylnorpentylone is 
available in powder, crystal, rock, capsule, and tablet forms. Examples exist where this drug has 
been surreptitiously sold as ‘ecstasy’/MDMA. 
 
WHO Review History 
N-Ethylnorpentylone has not been previously pre-reviewed or critically reviewed. 
 
Chemistry 
There is no specific information available about the routes of synthesis employed for the N-
ethylnorpentylone products circulating on the drug market but straightforward methods for its 
preparation exist without requiring access to precursors that are controlled internationally. 
 
Ease of convertibility into controlled substances 
There is no specific information available but it appears unlikely that N-ethylnorpentylone is 
converted into a substance currently controlled under the UN conventions. 
 
Similarity to known substances / Effects on the central nervous system 
The information currently available suggests that N-ethylnorpentylone is a psychomotor stimulant 
and that its molecular mechanism of action is also shared by other ring-substituted synthetic 
cathinones of the pyrovalerone type, such as MDPV (1-(2H-1,3-benzodioxol-5-yl)-2-(pyrrolidin-1-
yl)pentan-1-one) and α-PVP (1-phenyl-2-(pyrrolidin-1-yl)pentan-1-one), which are both listed in 
Schedule II of the Convention on Psychotropic Substances of 1971. 
 
General pharmacology 
The number of systematic studies available at this time is limited but it seems clear that N-
ethylnorpentylone is a psychomotor stimulant. In vitro, it has been demonstrated to block the 
reuptake of dopamine, norepinephrine and serotonin using rat brain synaptosomal preparations 
with preference for the dopamine system, thus, behaving cocaine- and MDPV-like rather than 
amphetamine-like. Animal studies confirmed that N-ethylnorpentylone increases locomotor 
activity and that it substituted for methamphetamine and cocaine in drug discrimination studies. 
 
Toxicology 
The LD50 value for N-ethylnorpentylone in the mouse (route of administration not reported) was 
determined at 240 mg/kg.  
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Adverse reactions in humans 
The detection of N-ethylnorpentylone in biological fluids collected from cases involving adverse 
effects (including deaths) confirmed that this drug is circulating on the market and used 
recreationally. Not all of the reported adverse effects could be causally linked to N-
ethylnorpentylone alone but there are indications that the observed effects are consistent with 
those seen with other psychomotor stimulants. The fact that N-ethylnorpentylone has been 
identified in products believed by users to represent ‘ecstasy’/MDMA means that users may be 
unaware of the additional risks of harm (e.g. potential exacerbation of a psychostimulant 
toxidrome) associated with the consumption of N-ethylnorpentylone either alone or in 
combination with other drugs.  
 
Dependence potential 
No studies carried out in humans or animals could be identified. 
 
Abuse potential 
In rodents, N-ethylnorpentylone fully substituted for methamphetamine and cocaine when using 
the drug discrimination paradigm. Mechanistically, results obtained from in vitro investigations 
confirmed that N-ethylnorpentylone inhibited the reuptake of the monoamines dopamine, 
norepinephrine and, to a lesser extent, serotonin, which is consistent with closely related 
pyrovalerone-type synthetic cathinones and cocaine with known abuse liability. The currently 
available data suggest that N-ethylnorpentylone might be liable to abuse.  
 
Therapeutic applications / usefulness 
N-Ethylnorpentylone is not known to have any therapeutic uses.  
 
Listing on WHO Model List of Essential Medicines 
N-Ethylnorpentylone is not listed.  
 
Marketing authorizations 
N-Ethylnorpentylone is not known to have any marketing authorizations. 
 
Industrial use 
N-Ethylnorpentylone is not known to have any agricultural, industrial or cosmetic uses even 
though it is available for purchase as a ‘research chemical’. 
 
Non-medical use 
The mode of use may involve the combinational use (intentionally or unintentionally) of other 
drugs and users may be unaware of the exact dose or compound being ingested (by whatever 
route). The information currently available suggests that N-ethylnorpentylone has been found in 
products sold as ‘ecstasy’/MDMA but there have been instances where other drugs have been 
detected in addition to N-ethylnorpentylone. N-Ethylnorpentylone may also be available in its own 
right and is advertised for sale by Internet retailers. 
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Nature and magnitude of public health problems 
Use of N-ethylnorpentylone appears to be limited to recreational substance users rather than the 
general population. The mode of use may involve the combinational use (intentionally or 
unintentionally) of other drugs and users may be unaware of the exact dose or compound being 
ingested (by whatever route). The fact that N-ethylnorpentylone has been identified in products 
believed by users to represent ‘ecstasy’/MDMA means that users may be unaware of the 
additional risks of harm (e.g. potential exacerbation of central nervous system effects resulting in a 
psychostimulant toxidrome) associated with the consumption of N-ethylnorpentylone either alone 
or in combination with other drugs. 
 
Licit production, consumption, and international trade 
N-Ethylnorpentylone is not known to have any agricultural, industrial or cosmetic uses even 
though it is available for purchase as a ‘research chemical’. 
 
Illicit manufacture and traffic 
A dramatic increase in seizures and reports linked to the detection of N-ethylnorpentylone has 
been predominantly reported in the USA from 2016 onward.  Purchase and importation of N-
ethylnorpentylone is unproblematic in UN Member States that do not exercise legislative control 
measures. Increasing numbers of reports have appeared that document the detection of N-
ethylnorpentylone on the drug market where it has been sold in the form of ‘ecstasy’/MDMA-like 
products.  
 
Current international controls and their impact 
N-Ethylnorpentylone is not controlled under the 1961, 1971 or 1988 United Nations Conventions. 
 
Current and past national controls 
N-Ethylnorpentylone is controlled in some UN Member States.  
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1.  Substance identification  
A. International Nonproprietary Name (INN) 
Not applicable. 
B. Chemical Abstract Service (CAS) Registry Number 
952016-47-6 (free base)  
17763-02-9 (hydrochloride salt) 
C. Other Chemical Names 
1-(3,4-Methylenedioxyphenyl)-2-ethylaminopentan-1-one 
1-(3,4-Methylenedioxyphenyl)-2-ethylamino-pentanone-(1) 
1-(1,3-Benzodioxol-5-yl)-2-(ethylamino)-1-pentanone 
1-(1,3-Benzodioxol-5-yl)-2-(ethylamino)pentan-1-one 
1-(2H-1,3-Benzodioxol-5-yl)-2-(ethylamino)-1-pentanone 
2-Ethylamino-1-(3,4-methylenedioxyphenyl)pentan-1-one 
N-Ethylnorpentylone 
N-Ethylpentylone [sic] 
 
D. Trade Names 
Not applicable. 
E. Street Names 
MDEVP; bk-EBDP; bk-ETHYL-K; bk-EPDP; ephylone; street names also include the 
chemical names. 
F. Physical Appearance 
The hydrochloride salt of N-ethylnorpentylone has been described as an off-white 
powder 1 and a neat solid. 2 In its pure form, N-ethylnorpentylone hydrochloride is 
expected to be odorless and white. 
 
G. WHO Review History 
N-Ethylnorpentylone has not been previously pre-reviewed or critically reviewed. A 
direct critical review is proposed based on information brought to WHO’s attention 
that N-ethylnorpentylone is clandestinely manufactured, of especially serious risk to 
public health and society, and of no recognized therapeutic use by any party. 
Preliminary data collected from literature and different countries indicated that this 
substance may cause substantial harm and that it has no medical use. 
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Page 10 of 30 
2. Chemistry 
A. Chemical Name 
IUPAC Name:  
1-(2H-1,3-Benzodioxol-5-yl)-2-(ethylamino)pentan-1-one 
CA Index Name:  
N-Ethyl-α-propyl-1,3-benzodioxole-5-ethanamine 
 
B. Chemical Structure 
Free base:  
 
 
Note: Asterisk (*) refers to a chiral center 
 
Molecular Formula: C14H19NO3 
Molecular Weight: 249.31 g/mol 
  
C. Stereoisomers 
The presence of a chiral center at the α-carbon of the side chain gives rise to the 
enantiomeric pair of (S)-N-ethylnorpentylone and (R)-N-ethylnorpentylone, 
respectively. However, on the streets N-ethylnorpentylone is most likely available 
as the racemic mixture. 
D. Methods and Ease of Illicit Manufacturing 
There is no specific information available about the routes of synthesis employed 
for the N-ethylnorpentylone products circulating on the market. Two procedures 
described in a patent disclosed by the Boehringer Ingelheim pharmaceutical 
company employed the N-alkylation of the primary amine precursor 2-amino-1-(2H-
1,3-benzodioxol-5-yl)pentan-1-one (a) using ethyl iodide/NaHCO3 in 95% ethanol 
(step i) heated at reflux for 2 h (Figure 1A).3, 4 An alternative reaction step employed 
an oxidation reaction using the 1-(2H-1,3-benzodioxol-5-yl)-2-(ethylamino)pentan-
1-ol precursor (a) (Figure 1B) using a chromic acid-pyridine complex where the 
reaction mixture was left to stand over night.4 Further details about the preparation 
of the precursors have not been disclosed. However, one convenient standard 
procedure frequently used for the synthesis of cathinones that might also be 
employable for the preparation of N-ethylnorpentylone (Figure 1C) could include 
the α-bromination (step i) of the 1-(2H-1,3-benzodioxol-5-yl)pentan-1-one 
precursor (a) and formation of the 1-(2H-1,3-benzodioxol-5-yl)-2-bromopentan-1-
O
O
H
N
O
*
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one intermediate (b). Reaction with N-ethylamine (step ii) gives N-
ethylnorpentylone (c), which may then be converted into a range of salts. This 
procedure has been employed for the preparation of N-ethylnorpentylone 
analogs.3, 4 The ketone species (a) is accessible by various routes. 
 
 
 
Figure 1. Examples of potential preparations of N-ethylnorpentylone.
3, 4
 
 
E. Chemical Properties 
Melting point 
 
238–241°C (hydrochloride salt)3, 4 
224 °C (salt form not reported)5 
 
Boiling point 
 
Information could not be identified. 
  
Solubility 
 
~ One mg/mL in phosphate buffered saline (pH 7.2) (hydrochloride salt).6 A sample 
of the hydrochloride salt (containing some traces of a bromide counter ion) was 
reported to be soluble in dimethyl sulfoxide, methanol, water and partially in 
dichloromethane.7 
F. Identification and Analysis  
Identification, especially when available in larger quantities than normally 
encountered in forensic toxicological work, is straightforward. Presumptive colour 
test results performed on submitted samples determined to contain N-
ethylnorpentylone have been published in the public domain.8 Results from 
analytical studies have been published and include data on crystallography,9, 10 gas 
O
O
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chromatography electron ionization mass spectrometry (MS),1, 5, 7, 11-14 electrospray 
ionization tandem MS,5, 11, 15 direct analysis in real time (DART) ionization based 
MS,16 nuclear magnetic resonance spectroscopy,5, 11 Fourier transform infrared 
spectroscopy,5, 11 1, 7, 12 and separation by high performance liquid 
chromatography,5, 15, 17. A method on stable isotope ratio analysis of synthesized N-
ethylnorpentylone has also been published.18 Analytical challenges may arise, for 
example when dealing with closely related isomers such as N,N-dimethylpentylone 
(1-(2H-1,3-benzodioxol-5-yl)-2-(dimethylamino)pentan-1-one) or 
isopropylnorbutylone (1-(2H-1,3-benzodioxol-5-yl)-2-[(propan-2-yl)amino]butan-1-
one). The implementation of adequate separation techniques might be needed to 
reduce the potential for misidentification, especially when dealing with samples 
(e.g. biological) that may only contain trace quantities.    
3. Ease of Convertibility Into Controlled Substances 
No information available. 
4. General Pharmacology 
The initial exploration of several synthetic ring-substituted cathinones carried out in 
the 1960s originated from the observation that many of these analogs were found 
to be stimulants of the central nervous system.e.g.3, 4, 19-21  
A. Routes of administration and dosage 
In patents disclosed by the Boehringer Ingelheim pharmaceutical company, the 
invented substances (including N-ethylnorpentylone and several other analogs) 
were claimed to be suitable for being used in various formulations such as oral 
(tablets, capsules or pills), parenteral (ampoules, vials or injectable liquids) or rectal 
administration (suppositories). Compound specific information was not provided 
but suggested dosage units for oral administrations were 1–150 mg (preferably 2–
75 mg) and 0.3–30 mg (preferably 1–25 mg) for parenteral administration.3 
Generally speaking, synthetic cathinones can be consumed by oral, parenteral and 
rectal routes of administration. Information received by the European Monitoring 
Centre for Drugs and Drug Addiction (EMCDDA) from reports on seized material 
suggests the existence of N-ethylnorpentylone-containing crystalline powders and 
pills containing logos normally associated with 3,4-methylenedioxy
methamphetamine (MDMA, ecstasy) pills.22 The Drug Enforcement Administration 
(DEA) reported seizures of powder, crystal, rock, capsule, and tablet forms,23 
suggesting its intended use for oral administration. Information published on user 
forums indicates that samples believed to be N-ethylnorpentylone were consumed 
by nasal insufflation, intravenous injection, oral and sublingual administratione.g.24-26 
but also rectal administration.27 Interpreting the information on common N-
ethylnorpentylone dosages based on descriptions shared on user forums is 
complicated by different routes of administration and examples of repetitive use 
ranging from low 10s to 100s mg.e.g. 24-35  
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B. Pharmacokinetics 
Detailed information could not be identified. The incubation of N-
ethylnorpentylone (37 °C, 2 h) with pooled mixed gender human liver microsomes 
revealed the detection of four metabolites arising from reduction of the keto group 
to the alcohol (1-(2H-1,3-benzodioxol-5-yl)-2-(ethylamino)pentan-1-ol), N-
dealkylation to the primary amine (2-amino-1-(2H-1,3-benzodioxol-5-yl)pentan-1-
one), demethylenation (1-(3,4-dihydroxyphenyl)-2-(ethylamino)pentan-1-one) and 
hydroxylation at one of the carbons of the α-carbon chain.15 All four metabolites 
were detected in authentic blood and oral fluid samples obtained from casework 
with the alcohol being reported as the most abundant metabolite in both types of 
samples.15  
C. Pharmacodynamics 
The number of published in vitro and in vivo studies at this time is limited but the 
available data suggest that N-ethylnorpentylone acts as a psychomotor stimulant in 
a number of assays.   
  
 In vitro data: 
 
In a monoamine transporter assay prepared from rat brain synaptosomes, N-
ethylnorpentylone was shown to function as a potent inhibitor at the dopamine 
(DAT), norepinephrine (NET) and serotonin transporter (SERT) with IC50 values of 37 
± 2 nM, 105 ± 14 nM, and 383 ± 27 nM, respectively, which indicated a preference 
for the dopamine system. In comparison, the analog 1-(2H-1,3-benzodioxol-5-yl)-2-
(methylamino)pentan-1-one (pentylone) was found to be less potent with IC50 
values of 154 ± 11 nM (DAT), 401 ± 27 nM9 (NET), and 1198 ± 59 nM (SERT). In 
addition, N-ethylnorpentylone was found to be inactive as a transporter substrate, 
which meant that it was unable to induce neurotransmitter release.36 
Mechanistically, this property is consistent with some other synthetic cathinone 
psychostimulants such as 1-(2H-1,3-benzodioxol-5-yl)-2-(pyrrolidin-1-yl)pentan-1-
one (MDPV) rather than, for example, 1-(2H-1,3-benzodioxol-5-yl)-2-
(methylamino)propan-1-one (methylone) that acts as a non-selective releaser.37, 38  
 
These results were consistent with studies investigating the binding, uptake and 
release of N-ethylnorpentylone compared to cocaine, methamphetamine and 
mazindol using HEK cells expressing human DAT, NET and SERT (Tables 1 and 2). N-
Ethylnorpentylone was found to show highest affinity at DAT compared to SERT and 
NET. The affinity of mazindol for DAT was 6.5-times higher than that observed for 
N-ethylnorpentylone. N-Ethylnorpentylone was also confirmed to be an inhibitor of 
monoamine transport with a potency rank order of DAT (IC50 = 54.9 nM) > NET (IC50 
= 114 nM) > SERT (IC50 = 460 nM) (Table 1). Superfusion release experiments 
furthermore confirmed that N-ethylnorpentylone behaved cocaine-like rather than 
methamphetamine-like given that it was not able to induce release (Table 2). 
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Table 1. Effects of N-ethylnorpentylone, cocaine, methamphetamine (METH) and Mazindol on [
125
I]RTI-55 binding to, and 
[
3
H]neurotransmitter uptake by, HEK- hDAT, HEK-hSERT and HEK-hNET cells (mean ± SEM). Modified from
39
 
HEK-hDAT N-Ethylnorpentylone Cocaine METH Mazindol 
[125I]RTI-55 binding: Ki (nM) 102 ± 15 591 ± 78 2,580 ± 180 15.7 ± 5.0 
[125I]RTI-55 binding: IC50 (nM) 106 ± 16 –   – – 
Hill slope -1.28 ± 0.08 -1.21 ± 0.15 -0.92 ± 0.10 -0.95 ± 0.05 
[3H]DA uptake IC50 (nM) 54.9 ± 7.3 314 ± 54 73 ± 16 – 
HEK-hSERT     
[125I]RTI-55 binding: Ki (nM) 893 ± 80 651 ± 52 172,000 ± 23,000  55 ± 17 
[125I]RTI-55 binding: IC50 (nM) 962 ± 86 – – – 
Hill slope -0.92 ± 0.08 -1.07 ± 0.10 -1.20 ± 0.09 -0.87 ± 0.04 
[3H]5-HT uptake IC50 (nM) 460 ± 120 286 ± 50 5,500 ± 1,400 – 
HEK-hNET     
[125I]RTI-55 binding: Ki (nM) 2,380 ± 620 4,000 ± 1,000 1,410 ± 120 -5.8 ± 1.7 
[125I]RTI-55 binding: IC50 (nM) 2,400 ± 630 – – – 
Hill slope -0.95 ± 0.05 -1.18 ± 0.22 -1.00 ± 0.10 -1.00 ± 0.12 
[3H]NE uptake IC50 (nM) 114 ± 29 373 ± 81 18.1 ± 4.4 – 
 
 
Table 2. Effects of N-ethylnorpentylone and methamphetamine on [
3
H]neurotransmitter release from HEK-
hDAT, HEK-hSERT and HEK-hNET superfusion assays (mean ± SEM). Modified from
39
 
HEK-hDAT N-Ethylnorpentylone Methamphetamine 
[3H]DA release EC50 (nM) ND (>10 μM) 511 ± 46 
Emax rel. to methamphetamine 
a Minimal 103.4 ± 4.0% 
HEK-hSERT   
[3H]5-HT release EC50 (nM) ND (>100 μM) 12,800 ± 2,300 
Emax rel. to methamphetamine 
a 7.2 ± 1.4% 103.4 ± 4.6% 
HEK-hNET   
[3H]NE release EC50 (nM) ND (>6.7 μM) 136 ± 42% 
Emax rel. to methamphetamine 
a 15.6 ± 8.4% 109.4 ± 0.6% 
a
 Emax: Maximal response relative to methamphetamine (100%: hDAT 10 μM; hSERT 0.3–1 mM; hNET 1–3 
μM). 
 
 
 In vivo data: 
  
The ED50 value determined for establishing central nervous stimulant action in the 
mouse (route of administration not reported) was of 2.75 mg/kg.3, 4  
 
Intraperitoneal administration of N-ethylnorpentylone to Sprague Dawley rats 
induced significant locomotor activity (highest at 20 mg/kg) with the 5 mg/kg dose 
being comparable with 5 mg/kg methamphetamine. Repeated administrations of N-
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ethylnorpentylone at 5 mg/kg led to increases in locomotor activity whereas 20 
mg/kg and 50 mg/kg administrations led to stereotypy (backward moving and head 
weaving). Acute and repeated administrations of 20 mg/kg N-ethylnorpentylone led 
to increases in time spent in the elevated plus maze test (35 min post injection; 
exploration for 5 min) but this was not observed at 5 mg/kg and 50 mg/kg.40  
 
Behavioral investigations comparing N-ethylnorpentylone with cocaine, (S)-(+)-
methamphetamine, and 3,4-methylenedioxymethampetamine (MDMA) confirmed 
that all test drugs induced a dose dependent increase in locomotor activity in male 
Swiss-Webster mice (Hsd:ND4, aged 2–3 months) (Table 3).41  
 
Table 3. Locomotor (horizontal) activity tests conducted over 8 h (10 min period).
a,41
 
 N-Ethylnorpentylone b Cocaine c METH d MDMA e 
ED50 (mg/kg) 
f 0.73 (0–30 min)  9.4 (0–30 min) 0.50 (20–50 min) 6.7 (40–70 min) 
Time Within 10 min; lasted 30–
130 min (0.5 to 2.5 mg/kg) g 
Within 10 min; 
lasted 120 min 
(20 mg/kg) h 
Within 10 min; 
lasted 180–270 
min (0.25, 0.5, 1 
and 2 mg/kg) i 
Within 10 min; 
lasted 260 min (2.5 
to 50 mg/kg) j 
a 
Time course/dose response study using male Swiss-Webster mice (Hsd:ND4, aged 2–3 months); intraperitoneal administration. 
 
b 
Administered doses: 0.25, 0.5, 1, 2.5, 5, 10 or 25 mg/kg; behavioral observations recorded on each mouse at 30, 120, and 480 min 
following 25 mg/kg N-ethylnorpentylone. It was stated that no unusual effects were observed following injection of this test drug. 
 
c 
Administered doses: 5, 10, 20, or 40 mg/kg. 
 
d 
METH: methamphetamine. Administered doses: 0.25, 0.5, 1, 2, or 4 mg/kg. 
 
e 
MDMA: 3,4-methylenedioxymethampetamine. Administered doses: 1, 2.5, 5, 10, 25, or 50 mg/kg. Behavioral observations recorded 
on each mouse at 30, 120, and 480 minutes following 50 mg/kg of this test drug.  
 
f 
Time period selected for analysis of dose-response data; time period in which test drug produced maximal effects. For N-
ethylnorpentylone: 0–30 min selected for analysis of dose-response data; earliest time period in which maximal stimulation first 
appeared as a function of dose.  
 
g 
Time- and dose- dependent stimulation of locomotor activity following 0.5 to 25 mg/kg.  
 
h
 Time- and dose- dependent stimulation of locomotor activity following 20 and 40 mg/kg.  
 
i
 Time- and dose- dependent stimulation of locomotor activity following 0.25 to 4 mg/kg dose range. 
 
j
 Time- and dose- dependent stimulation of locomotor activity following 2.5 to 50 mg/kg.  
 
 
5. Toxicology 
The LD50 value for N-ethylnorpentylone in the mouse (route of administration not 
reported) was determined at 240 mg/kg.3, 4  
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6. Adverse Reactions in Humans 
A number of case reports involving the detection of N-ethylnorpentylone have been 
reported in the scientific literature and are summarized in Table 4 below. The 
extent to which complete case histories were available differed and causal 
relationships to N-ethylnorpentylone alone could not be established in all cases. 
The examples provided in Table 4 include acute intoxications, death cases and 
analysis of oral fluid samples taken from recreational users of recreational 
substances.  
 
According to the background information and evaluation of ‘Three Factor Analysis’ 
(Factors 4, 5 and 6) for temporary scheduling document prepared by the US Drug 
Enforcement Administration, N-ethylnorpentylone has been detected in 25 
fatalities in Maryland (USA) that occurred between 2016 and 2017. In addition, 
approximately 125 toxicology reports confirmed the detection (urine and blood) of 
N-ethylnorpentylone in fatal cases observed between 2016 and 2018.23 It is unclear 
whether any of these cases are included in the information published in the 
literature and included in Table 4 below. 
 
Table 4. Case reports involving the detection of N-ethylnorpentylone 
Yeara Patent, 
age 
Comments (examples) Ref 
2016 M, 21 Death case. Suffered cardiac arrest following patient being 
described as agitated and diaphoretic with hot skin; haldol 
(5 mg) administered followed by cardiac arrest. CPR 
successful and vital signs at hospital showed hypotension 
and tachycardia. ECG showed sinus rhythm with premature 
atrial complexes and ST depression in inferior leads. 
Physical examination included sluggish pupillary reflexes, 
negative vestibulo-occular reflex, and myoclonus at the 
right lower extremity. Clinical laboratory analysis revealed 
hyperkalemia, hypoglycemia, rhabdomyolysis, liver failure, 
renal injury, elevated troponin, pH 6.80, and lactic acid of 
28 mg/dL. Tox screen positive for cannabinoid and ethanol 
level of 12 mg/dL. MRI showed bilateral restricted diffusion 
in the posterior parietal and occipital regions; treatment 
initiated with hypothermia cooling measures, intravenous 
fluids, and bicarbonate. ECG revealed severe 
encephalopathy. Cardiac arrest at treatment day 4. Details 
about detection of N-ethylnorpentylone not reported. 
42 
2017 M, 29 Death case. Agitated and combative patient (history of 
bipolar disorder); initial treatment with 5 mg haloperidol; 
pulse needed restoring en route to hospital. Patient was 
hypotensive and tachycardic with temperature ~41°C. 
Clinical laboratory analysis showed elevated troponins, 
rhabdomyolysis, hypoglycemia, hepatic and renal injury, 
14 
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respiratory failure and disseminated intravascular 
coagulation. Patient went into cardiac arrest and 
pronounced dead ~36 h after admission. Tox screen 
positive for opiates, benzodiazepines, amphetamines and 
cannabinoids. N-Ethylnorpentylone and lidocaine detected 
in antemortem blood but not quantified. Total morphine 
concentration of 40 ng/mL detected. Confirmatory tests 
for benzodiazepines, amphetamine and 
methamphetamine were negative.  
2018 M, 34 Death case. Found dead on floor; behaving erratically night 
prior. Peripheral blood: cocaine (trace), cocaethylene 
(trace), N-ethylnorpentylone (953 ng/mL), Cause of death: 
complications of acute N-ethylnorpentylone intoxication. 
43 
2018 M, 34 Death case. Brought to hospital in full cardiac arrest and 
pronounced dead; history of marijuana and alcohol use. 
Peripheral blood: cocaine (33 ng/mL), fentanyl (3 ng/mL), 
methamphetamine (938 ng/mL), amphetamine (86 ng/mL). 
Autopsy significant for pneumonia and early microscopic 
evidence of acute myocardial infarction. Cause of death: 
methamphetamine, cocaine, fentanyl, and N-
ethylnorpentylone toxicity.  
43 
2018 M, 25  Death case. Shot dead and found on street. Peripheral 
blood: hydrocodone (trace), alprazolam (30 ng/mL), N-
ethylnorpentylone (45 ng/mL), Cause of death: homicide. 
43 
2018 M, 25 Death case. Shot dead at gas station. Peripheral blood: 
alprazolam (25 ng/mL), cocaine (trace), ecgonine methyl 
ester (detected), 
N-ethylnorpentylone (31 ng/mL), Cause of death: 
homicide.  
43 
2018 M, –  
 
Death investigation. Blood analysis: N-ethylnorpentylone 
(positive), butylone (150 ng/mL), ketamine (870 ng/mL). 
15 
2018 M, –  
 
Death investigation; alleged “Molly” b use. Blood analysis: 
N-ethylnorpentylone (50,000 ng/mL), dibutylone (14 
ng/mL). 
15 
2018 M, –  
 
Unknown case history. Blood analysis: N-
ethylnorpentylone (1,200 ng/mL). 
15 
2018 M, 29 Unknown case history. Blood analysis: N-
ethylnorpentylone (1,140 ng/mL). 
15 
2018 M, 35 Homicide. Blood analysis: N-ethylnorpentylone 
postmortem (833 ng/mL); antemortem: positive. Butylone, 
midazolam (8.9 ng/mL) and THC (0.78 ng/mL) also 
detected. 
15 
2018 M, –  
 
Death investigation. Blood analysis: N-ethylnorpentylone 
(790 ng/mL), pentylone (96 ng/mL), dibutylone (13 ng/mL), 
butylone (12 ng/mL). 
15 
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2018 M, 28 Death investigation, suspected drug overdose. Blood 
analysis: N-ethylnorpentylone (600 ng/mL). 
15 
2018 M, 49 Death investigation, suspected drug overdose, suspected 
“bath salts” use. Blood analysis: N-ethylnorpentylone (550 
ng/mL), dibutylone (10 ng/mL), 4-chloro-α-PVP. 
15 
2018 M, –  
 
Death investigation. Blood analysis: N-ethylnorpentylone 
(540 ng/mL), dibutylone (11 ng/mL). 
15 
2018 M, –  
 
Death investigation, possible drug overdose. Blood 
analysis: N-ethylnorpentylone (430 ng/mL). 
15 
2018 M, –  
 
Death investigation. Blood analysis: N-ethylnorpentylone 
(358 ng/mL). 
15 
2018 M, –  
 
Death investigation following vehicular crash. Blood 
analysis: N-ethylnorpentylone (210 ng/mL), pentylone (200 
ng/mL) 
15 
2018 F, –  
 
Death investigation, homicide. Blood analysis: N-
ethylnorpentylone (160 ng/mL). 
15 
2018 M, 31 Death investigation, suicide, gunshot wound. Blood 
analysis: N-ethylnorpentylone (150 ng/mL). 
15 
2018 M, 33 Case history unknown. Blood analysis: N-ethylnorpentylone 
(100 ng/mL), methamphetamine (49 ng/mL), amphetamine 
(14 ng/mL), lorazepam (40 ng/mL).  
15 
2018 M, 47 Death investigation, suspected drug overdose. Blood 
analysis: N-ethylnorpentylone (90 ng/mL), carfentanil (1.3 
ng/mL).  
15 
2018 M, 23 Driving under the influence of drugs. Blood analysis: N-
ethylnorpentylone (87 ng/mL). 
15 
2018 M, 53 Death investigation. Blood analysis: N-ethylnorpentylone 
(86 ng/mL), U-47700, U-49900, tetrahydrofuranylfentanyl, 
acrylfentanyl (0.4 ng/mL), 4-ANPP. 
15 
2018 M, 40 Driving under the influence of drugs. Blood analysis: N-
ethylnorpentylone (41 ng/mL), fentanyl (7 ng/mL), 
norfentanyl (2.3 ng/mL).  
15 
2018 F, –  
 
Death investigation, suspected drug overdose. Blood 
analysis: N-ethylnorpentylone (38 ng/mL), dibutylone (40 
ng/mL), butylone (15.3 ng/mL), “fluoroisobutyrylfentanyl”. 
15 
2018 M, –  
 
Driving under the influence of drugs. Blood analysis: N-
ethylnorpentylone (34.3 ng/mL). 
15 
2018 M, 25 Death investigation. Blood analysis: N-ethylnorpentylone 
(24 ng/mL), alprazolam (28 ng/mL), THC (1.6 ng/mL). 
15 
2018 M, 36 Driving under the influence of drugs. Blood analysis: N-
ethylnorpentylone (23 ng/mL) methamphetamine (55 
ng/mL), amphetamine (<5 ng/mL). 
15 
2018 M, 32 Driving under the influence of drugs. Blood analysis: N-
ethylnorpentylone (21 ng/mL) clonazepam (23 ng/mL). 
15 
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2018 M, –  
 
Death investigation, suspected drug overdose, found 
deceased at home, suspected to have snorted cocaine or 
heroin. Blood analysis: N-ethylnorpentylone (18.4 ng/mL), 
furanylfentanyl, 4-ANPP, cocaine (130 ng/mL), THC (0.86 
ng/mL). 
15 
2018 M, –  
 
Death investigation. Blood analysis: N-ethylnorpentylone 
(12 ng/mL). 
15 
2018 M, 30 Recreation drug use (“Molly”); oral fluid sample collected 
from recreational user at dance music festival. Blood 
analysis: N-ethylnorpentylone (1,377 ng/mL), eutylone, 
MDA, alprazolam. 
15 
2018 M, 20 Recreation drug use (“Molly”); oral fluid sample collected 
from recreational user at dance music festival. Blood 
analysis: N-ethylnorpentylone (132.9 ng/mL), eutylone, 
THC (40.5). 
15 
2018 F, 24 Recreation drug use (“Molly”); oral fluid sample collected 
from recreational user at dance music festival. Blood 
analysis: N-ethylnorpentylone (35.2 ng/mL), alprazolam. 
15 
2018 F, 21 Recreation drug use (“Molly”); oral fluid sample collected 
from recreational user at dance music festival. Blood 
analysis: N-ethylnorpentylone (31.5 ng/mL), MDA (35.7 
ng/mL), THC (2.7 ng/mL). 
15 
2018 F, 34 Recreation drug use (“Molly”); oral fluid sample collected 
from recreational user at dance music festival. Blood 
analysis: N-ethylnorpentylone (12.6 ng/mL), THC. 
15 
2018 M, 32 Death case. Patient displayed psychomotor agitation and 
aggressiveness, then fainted at rave party. External showed 
facial swelling, cyanosis at extremities and yellowish liquid 
emanating from mouth and nostrils. Internal examination 
showed generalized hemorrhage of pulmonary alveoli, 
abnormal increase in liver size and absence of urine in 
bladder. Whole blood analysis: N-ethylnorpentylone (170 
ng/mL). 
36 
2018 M, 18 Intoxication case. Display of agitation and signs of several 
injuries at rave party. Patient presented with tachycardia 
(176 bpm) and mydriatic pupils, oscillated between 
psychomotor agitation and neurological depression. Serum 
analysis: N-ethylnorpentylone (7 ng/mL) and detection in 
urine. Patient recovered after a few hours; discharged 
after 12 h. 
36 
2018 F, 26 Intoxication case. Found unconscious in apartment with 
sphincter release, attended party in previous night and 
suspected to have consumed ecstasy pills and marijuana. 
At hospital, patient appeared confused, sleepy, displayed 
disconnected speech and episodes of visual hallucinations. 
36 
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Urine analysis: N-ethylnorpentylone and MDMA; not 
detected in serum. Patient discharged after 24 h 
observation. 
2018 M, 19 Intoxication case. Patient attended rave party, stayed 14 h 
consuming various drugs and alcohol. He reportedly 
consumed five ecstasy tablets, ingested one LSD blotter 
hit, smoked two packs of cigarettes and drank an 
undetermined amount of the Brazilian alcoholic beverage 
“catuaba”. Patient experienced palpitations and visited 
hospital; at physical examination he appeared agitated, 
with palpitations and tachycardia (180 bpm). Urine tox 
screening showed MDMA, N-ethylnorpentylone, caffeine 
and cotinine; LSD not detected; serum analysis: alcohol 
(0.8 g/L), N-ethylnorpentylone (19 ng/mL), and MDMA. 
Patient treated with diazepam and metoclopramide and 
discharged 24 h later. 
36 
 M, 35 Intoxication case. Patient reported of having been 
consuming alcohol and other drugs of abuse for two 
consecutive days. He was found unconscious, with 
neurological depression (Glasgow 5) and anisocoria. At 
hospital, patient received fentanyl, midazolam for 
orotracheal intubation, tramadol and dipyrone. After 6 h of 
admission, patient evolved to neurogenic shock, and 
decerebration. Serum analysis: N-ethylnorpentylone (149 
ng/mL). Symptoms remained unchanged. At 6 days 
vertebral artery dissection identified affecting brainstem; 
and cerebrovascular hemorrhage of the brainstem was 
diagnosed. Thirty-five days later, patient was discharged in 
a vegetative state with neurological damage to the third 
cranial nerve (oculomotor nerve), which made it 
impossible for the patient to open his eyes. 
36 
 M, 26 Intoxication case: patient with previous history of mental 
disorders admitted to psychiatry emergency unit for 
differential diagnosis of drug misuse; presented with 
symptoms of psychosis, paranoia, sleeplessness and 
inconsistent speech. Serum analysis: N-ethylnorpentylone 
(61 ng/mL). Patient required sedation with midazolam and 
started treatment with valproic acid, risperidone, 
haloperidol and levopromazine. 
36 
a
 Year of publication. 
b
 “Molly”: frequently referring to pure crystalline form of 3,4-methylenedioxymethamphetamine (MDMA) 
and/or drugs marketed as having MDMA-like effects. 
 
 
41st ECDD (2018): N-ethylnorpentylone     
 
 
 
Page 21 of 30 
7. Dependence Potential 
A. Animal Studies 
Studies could not be identified. 
B. Human Studies 
Studies could not be identified. 
8. Abuse Potential 
A. Animal Studies 
Drug discrimination studies (male Sprague-Dawley rats; two-lever choice 
methodology; intraperitoneal administration; FR10 schedule) corroborated that N-
ethylnorpentylone fully substituted for the discriminative stimulus effects of 
cocaine (ED50 = 1.98 mg/kg; 10 mg/kg cocaine used for training),
44 and (S)-(+)-
methamphetamine (ED50 = 1.65 mg/kg; 1 mg/kg (S)-(+)-methamphetamine used for 
training).45 Partial substitution (51% at 10 mg/kg N-ethylnorpentylone) was 
observed in rats trained to discriminate MDMA (1.5 mg/kg) from saline. It was also 
found that the response rate decreased following 10 and 25 mg/kg N-
ethylnorpentylone, with the maximum effect (27% of vehicle control) following 
administration of 25 mg/kg.46 
B. Human Studies 
Studies could not be identified. 
9. Therapeutic Applications and Extent of Therapeutic Use and Epidemiology of 
Medical Use 
Information about therapeutic use could not be identified. 
10. Listing on the WHO Model List of Essential Medicines 
N-Ethylnorpentylone is not listed. 
11. Marketing Authorizations (as a Medicinal Product) 
N-Ethylnorpentylone was never marketed as a medicinal product.   
12. Industrial Use 
Information about recorded industrial use could not be identified. 
13. Non-Medical Use, Abuse and Dependence 
Use of N-ethylnorpentylone appears to be limited to recreational substance users rather 
than the general population. The mode of use may involve the combinational use 
(intentionally or unintentionally) of other drugs and users may be unaware of the exact 
dose or compound being ingested (by whatever route). Dependence-producing properties 
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in humans have not been studied. The information currently available suggests that N-
ethylnorpentylone has been found in products sold as ‘ecstasy’/MDMA.8, 23, 47 but there 
have been instances where other drugs have been detected in addition to N-
ethylnorpentylone.8, 22 N-Ethylnorpentylone may also be available in its own right and is 
advertised for sale by Internet retailers.  
14. Nature and Magnitude of Public Health Problems Related to Misuse, Abuse and 
Dependence 
Surveys that systematically assess the prevalence of N-ethylnorpentylone use within the 
general population are not available. The detection of N-ethylnorpentylone in biological 
fluids has been described in cases involving impaired driving (Section 6). The fact that N-
ethylnorpentylone has been identified in products believed by users to represent 
‘ecstasy’/MDMA means that users may be unaware of the additional risks of harm (e.g. 
potential exacerbation of a psychostimulant toxidrome) associated with the consumption 
of N-ethylnorpentylone either alone or in combination with other drugs.  
15. Licit Production, Consumption and International Trade 
It is used as a reference material for scientific research. It is not known to have any 
agricultural, industrial or cosmetic uses even though it is available for purchase as a 
‘research chemical’.  
 
Please refer to Annex 1: Report on WHO questionnaire for review of psychoactive 
substances. 
16. Illicit Manufacture and Traffic and Related Information 
Reports have been received from the European Early-Warning System on new 
psychoactive substances that N-ethylnorpentylone (first notified to EMCDDA in January 
201648) was encountered in seizures and collected specimen (crystalline powder, powder, 
urine, tablets) in Austria, Belgium, Bosnia and Herzegovina, Czech Republic, France, 
Germany, Greece, Italy, Hungary, Ireland, Latvia, Lithuania, Malta, Norway, Portugal, 
Romania, Slovenia, Spain, Sweden, Turkey, and United Kingdom.22 
 
Reports about detections of N-ethylnorpentylone in the United States of America (USA) 
started to appear in May 201449. The National Forensic Laboratory Information System 
(NFLIS), which is dedicated to the collection of drug cases submitted by State and local 
laboratories in the USA, is currently registering an increase in reports (Table 5). According 
to the background information and evaluation of ‘Three Factor Analysis’ (Factors 4, 5 and 
6) for temporary scheduling document prepared by the US Drug Enforcement 
Administration, a total number of 6,035 reports (local and State forensic laboratories) on 
the identification of N-ethylnorpentylone were received between January 2013 and 
December 2017.23 Seizures of N-ethylnorpentylone increased since 2016 from 2,074 
reports (from 39 States) to 3,955 reports (from 39 States) in 2017. It was furthermore 
stated that seizures of N-ethylnorpentylone by the U.S. Customs and Border Protection 
emerged in 2016.23 The net weight of 338 drug exhibits pertaining to trafficking, 
41st ECDD (2018): N-ethylnorpentylone     
 
 
 
Page 23 of 30 
distribution and abuse amounted to approximately 82 kg. Seizures indicate that N-
ethylnorpentylone is available in powder, crystal, rock, capsule, and tablet forms. 23 The 
number of N-ethylnorpentylone identifications published in the Drug Enforcement 
Administration's (DEA) Special Testing and Research Laboratory’s Emerging Trends 
Program increased from 63 (out of 347 cathinone identifications, 18.2%) in 201650 to 63 
(out of 347, 18.2%) in 2016 to 201 (out of 369 cathinone identifications, 54.5%) in 2017.51 
In the first quarter of 2018, 17 out of 29 cathinone identifications (58.6%) were attributed 
to N-ethylnorpentylone.52  
 
Table 5. Number of reports received by the U.S. National Forensic Laboratory Information System 
(NFLIS) related to detections of N-ethylnorpentylone in law enforcement operations 
Year a Numbers b α-PVP c MDMA d Meth e Ref 
2013 (MY) NR 1,202 2,423 100,045 NFLIS53 
2013 (AR) NR 2,440 4,798 206,784 NFLIS54 
2014 (MY) c NR 1,950 2,224 117,318 NFLIS55 
2014 (AR) NR 3,905 4,902 236,175 NFLIS56 
2015 (MY) NR NR 2,421 133,374 NFLIS57 
2015 (AR) NR NR 5,188 277,823 NFLIS58 
2016 (MY) 457 666 2,901 155,535 NFLIS59 
2016 (AR) f 1,720 1,036 5,726 314,872 NFLIS60 
2017 (MY) 2,520 512 2,695 170,300 NFLIS61 
a 
MY: mid-year report (January to June); AR: annual report (January to December). 
b 
NR: not reported
 
c 
α-PVP: alpha-pyrrolidinopentiophenone 
d 
MDMA: 3,4-Methylenedioxymethamphetamine 
e 
Meth: methamphetamine 
f
 Revised April 2018 
 
Detections of N-ethylnorpentylone have also been reported to the United Nations Office 
on Drugs and Crime’s (UNODC) Early Warning Advisory on New Psychoactive Substances. 
Identifications of N-ethylnorpentylone were reported by one country in 2015, 25 countries 
in 2016, 10 countries in 2017, and 3 countries in 2018 (as of 25 August 2018).62 
 
Please also refer to Annex 1: Report on WHO questionnaire for review of psychoactive 
substances. 
17. Current International Controls and Their Impact 
N-Ethylnorpentylone is not controlled under the 1961, 1971 or 1988 United Nations 
Conventions. 
18. Current and Past National Controls 
Refer to Annex 1: Report on WHO questionnaire for review of psychoactive substances. 
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19. Other Medical and Scientific Matters Relevant for a Recommendation on the 
Scheduling of the Substance 
Detections of N-ethylnorpentylone may be under-reported given that the substance might 
not be routinely screened for in all laboratories receiving samples for analysis.  
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